Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry

Francesco Baglieri, Francesca Anastasio, Maria Rita Bongiorno, Agostino Igor Mirulla, Aurora Giannetti, Bina Claudia Guarneri, Cinzia Di Dio, Concetta Di Vito, Gaia Elena Maria Condello, Giuseppe Cannata, Giuseppe Monfrecola, Ida Di Mattei, Livia Maria Caterina Prezzemolo, Loredana Zappala', Lucilla De Angelis, Maria Rita Lo Forte, Rosa Giuseppa Angileri, Selene Murgia, Sigfrido Giuseppe La Greca

Risultato della ricerca: Article

15 Citazioni (Scopus)

Abstract

Background The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in 8.3% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4.3% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P < 0.05). Independent factors associated with LTBI were male sex [odds ratio (OR) 1.30, 95% confidence interval (CI) 1.04-1.62; P = 0.02], age over 55 years (OR 2.93, 95% CI 2.18-3.93; P < 0.001) and being entered into a conventional treatment (OR 3.83, 95% CI 3.10-4.74; P < 0.001). Positive history of tuberculosis was seen in 1% of patients (n = 49). Conclusions The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.
Lingua originaleEnglish
pagine (da-a)1613-1620
Numero di pagine8
RivistaBritish Journal of Dermatology
Volume172
Stato di pubblicazionePublished - 2015

Fingerprint

Latent Tuberculosis
Psoriasis
Registries
Tuberculin Test
Odds Ratio
Confidence Intervals
Skin Tests
Tuberculosis
Therapeutics
Ficusin
Sex Ratio
Biological Products

All Science Journal Classification (ASJC) codes

  • Dermatology

Cita questo

Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry. / Baglieri, Francesco; Anastasio, Francesca; Bongiorno, Maria Rita; Mirulla, Agostino Igor; Giannetti, Aurora; Guarneri, Bina Claudia; Di Dio, Cinzia; Di Vito, Concetta; Condello, Gaia Elena Maria; Cannata, Giuseppe; Monfrecola, Giuseppe; Di Mattei, Ida; Prezzemolo, Livia Maria Caterina; Zappala', Loredana; De Angelis, Lucilla; Lo Forte, Maria Rita; Angileri, Rosa Giuseppa; Murgia, Selene; La Greca, Sigfrido Giuseppe.

In: British Journal of Dermatology, Vol. 172, 2015, pag. 1613-1620.

Risultato della ricerca: Article

Baglieri, F, Anastasio, F, Bongiorno, MR, Mirulla, AI, Giannetti, A, Guarneri, BC, Di Dio, C, Di Vito, C, Condello, GEM, Cannata, G, Monfrecola, G, Di Mattei, I, Prezzemolo, LMC, Zappala', L, De Angelis, L, Lo Forte, MR, Angileri, RG, Murgia, S & La Greca, SG 2015, 'Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry', British Journal of Dermatology, vol. 172, pagg. 1613-1620.
Baglieri, Francesco ; Anastasio, Francesca ; Bongiorno, Maria Rita ; Mirulla, Agostino Igor ; Giannetti, Aurora ; Guarneri, Bina Claudia ; Di Dio, Cinzia ; Di Vito, Concetta ; Condello, Gaia Elena Maria ; Cannata, Giuseppe ; Monfrecola, Giuseppe ; Di Mattei, Ida ; Prezzemolo, Livia Maria Caterina ; Zappala', Loredana ; De Angelis, Lucilla ; Lo Forte, Maria Rita ; Angileri, Rosa Giuseppa ; Murgia, Selene ; La Greca, Sigfrido Giuseppe. / Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry. In: British Journal of Dermatology. 2015 ; Vol. 172. pagg. 1613-1620.
@article{8b86e547d6364f4996f9167dc1687afc,
title = "Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry",
abstract = "Background The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in 8.3{\%} of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4.3{\%} (19 of 444) of patients on adalimumab to 31{\%} (eight of 26) of those on psoralen-ultraviolet A (P < 0.05). Independent factors associated with LTBI were male sex [odds ratio (OR) 1.30, 95{\%} confidence interval (CI) 1.04-1.62; P = 0.02], age over 55 years (OR 2.93, 95{\%} CI 2.18-3.93; P < 0.001) and being entered into a conventional treatment (OR 3.83, 95{\%} CI 3.10-4.74; P < 0.001). Positive history of tuberculosis was seen in 1{\%} of patients (n = 49). Conclusions The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.",
author = "Francesco Baglieri and Francesca Anastasio and Bongiorno, {Maria Rita} and Mirulla, {Agostino Igor} and Aurora Giannetti and Guarneri, {Bina Claudia} and {Di Dio}, Cinzia and {Di Vito}, Concetta and Condello, {Gaia Elena Maria} and Giuseppe Cannata and Giuseppe Monfrecola and {Di Mattei}, Ida and Prezzemolo, {Livia Maria Caterina} and Loredana Zappala' and {De Angelis}, Lucilla and {Lo Forte}, {Maria Rita} and Angileri, {Rosa Giuseppa} and Selene Murgia and {La Greca}, {Sigfrido Giuseppe}",
year = "2015",
language = "English",
volume = "172",
pages = "1613--1620",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry

AU - Baglieri, Francesco

AU - Anastasio, Francesca

AU - Bongiorno, Maria Rita

AU - Mirulla, Agostino Igor

AU - Giannetti, Aurora

AU - Guarneri, Bina Claudia

AU - Di Dio, Cinzia

AU - Di Vito, Concetta

AU - Condello, Gaia Elena Maria

AU - Cannata, Giuseppe

AU - Monfrecola, Giuseppe

AU - Di Mattei, Ida

AU - Prezzemolo, Livia Maria Caterina

AU - Zappala', Loredana

AU - De Angelis, Lucilla

AU - Lo Forte, Maria Rita

AU - Angileri, Rosa Giuseppa

AU - Murgia, Selene

AU - La Greca, Sigfrido Giuseppe

PY - 2015

Y1 - 2015

N2 - Background The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in 8.3% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4.3% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P < 0.05). Independent factors associated with LTBI were male sex [odds ratio (OR) 1.30, 95% confidence interval (CI) 1.04-1.62; P = 0.02], age over 55 years (OR 2.93, 95% CI 2.18-3.93; P < 0.001) and being entered into a conventional treatment (OR 3.83, 95% CI 3.10-4.74; P < 0.001). Positive history of tuberculosis was seen in 1% of patients (n = 49). Conclusions The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.

AB - Background The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in 8.3% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4.3% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P < 0.05). Independent factors associated with LTBI were male sex [odds ratio (OR) 1.30, 95% confidence interval (CI) 1.04-1.62; P = 0.02], age over 55 years (OR 2.93, 95% CI 2.18-3.93; P < 0.001) and being entered into a conventional treatment (OR 3.83, 95% CI 3.10-4.74; P < 0.001). Positive history of tuberculosis was seen in 1% of patients (n = 49). Conclusions The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.

UR - http://hdl.handle.net/10447/345127

M3 - Article

VL - 172

SP - 1613

EP - 1620

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

ER -